Trial reportThe European respiratory journal2018
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma.
Trial report in The European respiratory journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 124 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA)
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma
Who cites it
124 citing papers in PubMed, 6 syntheses or guidelines pooled it, 245 citations in OpenAlex.
- Benralizumab in severe eosinophilic asthma: a comprehensive systematic review and meta-analysis of randomized controlled trials evaluating lung function, asthma control, and safety outcomes.Systematic reviews · 2026Pooled it
- Comparative efficacy of biologics for uncontrolled asthma patients with chronic rhinosinusitis or nasal polyps: a systematic review and network meta-analysis.BMC pulmonary medicine · 2025Pooled it
- The clinical and pathological histology efficacy of biological therapy for severe asthma with a phenotype of type 2 inflammation - systematic review.Frontiers in immunology · 2025Pooled it
- Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review.Advances in therapy · 2023Pooled it
- Anti-IL-5 therapies for asthma.The Cochrane database of systematic reviews · 2022Pooled it
- Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.Respiratory research · 2021Pooled it
- Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study.Advances in therapy · 2025Trial
- Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial.Lancet (London, England) · 2022Trial
- Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.Respiratory research · 2021Trial
- Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma.PloS one · 2021Trial
- Small Airways Disease Adversely Impacts the Response to Biologic Therapies in Severe Asthma.Pulmonary therapy · 2026Article
- Misconceptions of Traits to Predict Response to Inhaled Corticosteroid and Bronchodilator Therapies in Asthma: A Narrative Review.Pulmonary therapy · 2026Review
- Identification of predictive factors for clinical remission and comparison of 3 definitions in Japanese patients with severe asthma treated with biologics.The journal of allergy and clinical immunology. Global · 2026Article
- Benralizumab in Severe Eosinophilic Asthma: Toward Disease Control and Evolving Treatment Paradigms.Journal of inflammation research · 2026Review
- Depemokimab demonstrates efficacy in patients with type 2 asthma with comorbid CRSwNP: Phase III SWIFT-1/-2 analysis.Frontiers in allergy · 2026Article
- Precision Medicine for Asthma: Tailored to its Severity and Endotype/Phenotype.Allergy, asthma & immunology research · 2026Review
- Benralizumab: Bringing winds of change to eosinophil-associated diseases.The World Allergy Organization journal · 2025Review
- Detection and prediction of real-world severe asthma phenotypes by application of machine learning to electronic health records.The journal of allergy and clinical immunology. Global · 2025Article
- The immunology of asthma and chronic rhinosinusitis.Nature reviews. Immunology · 2025Review
- Is Biologic Therapy an Effective Tool for Achieving Remission in Severe Asthma? A Retrospective Study in Central Romania.Life (Basel, Switzerland) · 2025Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benralizumab is an anti-eosinophilic monoclonal antibody that reduces exacerbations and improves lung function for patients with severe, uncontrolled asthma with eosinophilic inflammation. We evaluated the impact of baseline factors on benralizumab efficacy for patients with severe asthma.This analysis used pooled data from the SIROCCO (ClinicalTrials.gov identifier NCT01928771) and CALIMA (ClinicalTrials.gov identifier NCT01914757) Phase III studies. Patients aged 12-75 years with severe, uncontrolled asthma receiving high-dosage inhaled corticosteroids plus long-acting β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.